What the Science Shows

Protandim has been shown in two human clinical trials to significantly increase the production of the body's own antioxidant enzymes, which are vastly superior in neutralizing free radicals and minimizing oxidative stress.

Human study #1 (2006)

After 30 days, Protandim completely eliminates the age-dependant increase in oxidative stress.

After 120 days, Protandim raises production of catalase 54% and SOD 34%. Protandim also increased production of approximately 20 additional antioxidant enzymes.

Human study #2 (2008)

Production of glutathione, a key antioxidant compound, is increased 300%.

Protandim's synergistic formulation provides many times the antioxidant power than any food or conventional supplements.

Study #1 (2009)

Protandim prevented the formation of scar tissue in the heart.

It also increased the expression of antioxidant, anti-inflammatory, and anti-fibrotic genes.

Protandim lowered levels of osteopontin by 50%: osteopontin leads to scar tissue formation and contributes to heart failure.

Study #2 (2009)

Protandim produced significant increase in the expression levels of SOD and catalase.

Skin tumor incidence was reduced 33%-57%.

Study #3 - Independently sponsored by American Heart Association and the National Institute of Health (2011)

Protandim was shown to inhibit the growth of cells that contribute to blockage of arteries and blood vessels.

Researchers found that Protandim increased the production of the body's Nrf2 signaling molecules.

They also found that Protandim suppressed the over-proliferation of cells that line blood vessel walls and contribute to blood vessel blockage.

Published Research Studies

Protandim has been scientifically validated over and over in independently funded peer-reviewed published studies (the gold standard of medical research) conducted at major universities. You can view this scientific breakthrough information at the U.S. National Library of Medicine’s website. See studies below!

Protandim has been studied by numerous universities in their own funded trials because scientists who know about the true science of oxidative stress are so excited about the potential. Here are the 11 independently funded peer-reviewed published studies on Protandim:

OXIDATIVE STRESS - The Induction of Human Superoxide Dismutase and Catalase in Vivo: A Fundamentally New Approach to Antioxidant Therapy
University of Colorado Denver
Free Radical Biology & Medicine 40 (2006)
Read the Abstract
Download the Full Article
GLUTATHIONE - Synergistic Induction of Heme Oxygenase-1 by the Components of an Antioxidant Supplement Protandim 
University of Colorado Denver
Free Radical Biology and Medicine (2008)
Read the Abstract
Download the Full Article
SKIN CANCER - Protandim, a Fundamentally New Antioxidant Approach in Chemoprevention Using Mouse Two-Stage Skin Carcinogens as a Model
Louisiana State University
PLoS ONE (2009)
Read the Abstract
Download the Full Article
HEART DISEASE - Chronic Pulmonary Artery Pressure Elevation is Insufficient to Explain Right Heart Failure
Virginia Commonwealth University
Circulation, Journal of the American Heart Association (November 2, 2009)
Read the Abstract
Download the Full Article
MUSCULAR DYSTROPHY - The Dietary Supplement Protandim Decreases Plasma Osteopontin and Improves Markers of Oxidative Stress in Muscular Dystrophy Mdx Mice
Harvard University
Journal of Dietary Supplements (2010)
Read the Abstract
Download The Full Article
CHEMOPREVENTIVE EFFECTS - The Chemopreventive Effects of Protandim: Modulation of p53 Mitochondrial Translocation and Apoptosis during Skin Carcinogenesis
Louisiana State University
PLoS ONE (2010)

BYPASS GRAFTS - Protandim Attenuates Intimal Hyperplasia in Human Saphenous Veins Cultured Ex Vivo via a Catalase-Dependent Pathway
Ohio State University
Free Radical Biology & Med. (Dec 14, 2010)

SKIN CANCER - The Role of Manganese Superoxide Dismutase in Skin Cancer
Louisiana State University
Enzime Research (2011)

NRF2 ACTIVATION - Oxidative Stress in Health and Disease: The Therapeutic Potential of Nrf2 Activation
University of Colorado Denver
Molecular Aspects of Medicine (2011)

Check out the 2 latest published independent studies!!!

NEW Antioxidants for the Treatment of Patients with Severe Angioproliferative Pulmonary Hypertension?Virginia Commonwealth University
Antioxid Roedox Signal. (Sept 28, 2012)

NEW Phytochemical activation of Nrf2 protects human coronary artery endothelial cells against an oxidative challengeColorado State University
Oxid Med Cell Longev. 2012;2012:132931. Epub (May 22, 2012)

Because of the many ongoing studies, this page might not be up to date. Click here to view all the new published peer-reviewed researches completed to date on Protandim!

Institutions Currently Studying Protandim

* Ohio State University
* University of Minnesota
* Vanderbilt University
* University of Michigan
* University of Colorado
* University of Kentucky
* Denver Health Medical Center
* University of Florida
* Glamorgan University, Wales
* Sahigrenska Univerity Hospital, Goteborg, Sweden
* University or Toronto/St. Michelle’s Hospital, Canada
* University Hospital, Brno, Czech Republic
* Mexican Institute of Social Security, Mexico City

Health Conditions being Researched

The health topics currently under scientific investigation or in planning stages deal with the alleviation of oxidative stress linked to the following conditions:

* Altitude sickness
* Skin cancer
* Photoaging of the skin
* Renal failure
* Osteoarthritis
* HIV/AIDS-associated lipodystrophy
* Pulmonary hypertension
* Periodontal disease
* Heart disease
* Coronary artery bypass graft failure
* Asthma
* Metabolic syndrome
* Non-alcoholic fatty liver disease
* Optic neuropathy


Peer-Reviewed Published Studies show Protandim increases levels of the anti-aging enzymes: 

Superoxide Dismutase by 30%
Catalase by 54%
Glutathione by 300%

Due to growing excitement and an expanding knowledge of Protandim's capabilities, numerous more universities have initiated and funded more of their own studies of Protandim. 
Some of these new studies have concluded and can be viewed at